Previous studies have shown that genes can be switched on or off by age, environmental factors, diseases, and lifestyles. The open or compact structures of chromatin is a crucial factor that affects gene expression. Epigenetics refers to hereditary mechanisms that change gene expression and regulations without changing DNA sequences. Epigenetic modifications, such as DNA methylation, histone modification, and non-coding RNA interaction, play critical roles in cell differentiation and disease processes. The conventional approach requires the use of a few million or more cells as starting material. However, such quantity is not available when samples from patients and small lab animals are examined. Microfluidic technology offers advantages to utilize low-input starting material and for high-throughput. In this thesis, I developed novel microfluidic technologies to study epigenomic regulations, including 1) profiling epigenomic changes associated with LPS-induced murine monocytes for immunotherapy, 2) examining cell-type-specific epigenomic changes associated with BRCA1 mutation in breast tissues for breast cancer treatment, and 3) developing a novel microfluidic oscillatory hybridized ChIRP-seq assay to profile genome-wide lncRNA binding for numerous human diseases. We used 20,000 and 50,000 primary cells to study histone modifications in inflammation and breast cancer of BRCA1 mutation, respectively. In the project of whole-genome lncRNA bindings, our microfluidic ChIRP-seq assay, for the first time, allowed us to probe native lncRNA bindings in mouse tissue samples successfully. The technology is a promising approach for scientists to study lncRNA bindings in primary patients. Our works pave the way for low-input and high-throughput epigenomic profiling for precision medicine development. / Doctor of Philosophy / Traditionally, physicians treat patients with a one-size-fits-all approach, in which disease prevention and treatment are designed for the average person. The one-size-fits-all approach fits many patients, but does not work on some. Precision medicine is launched to improve the low efficiency and diminish side effects, and all of these drawbacks are happening in the traditional approaches. The genomic, transcriptomic, and epigenomic data from patients is a valuable resource for developing precision medicine. Conventional approaches in profiling functional epigenomic regulation use tens to hundreds of millions cells per assay, that is why applications in clinical samples are restricted for several decades. Due to the small volume manipulated in microfluidic devices, microfluidic technology exhibits high efficiency in easy operation, reducing the required number of cells, and improving the sensitivity of assays. In order to examine functional epigenomic regulations, we developed novel microfluidic technologies for applications with the small number of cells. We used 20,000 cells from mice to study the epigenomic changes in monocytes. We also used 50,000 cells from patients and mice to study epigenomic changes associated with BRCA1 mutation in different cell types. We developed a novel microfluidic technology for studying lncRNA bindings. We used 100,000-500,000 cells from cell lines and primary tissues to test several lncRNAs. Traditional approaches require 20-100 million cells per assay, and these cells are infected by virus for over-producing specific lncRNA. However, our technology just needs 100,000 cells (non-over-producing state) to study lncRNA bindings. To the best of our knowledge, this is the first allowed us to study native lncRNA bindings in mouse samples successfully. Our efforts in developing microfluidic technologies and studying epigenomic regulations pave the way for precision medicine development.

Yes / The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor and member of the basic helix-loop-helix-PAS family. AHR is activated by numerous dietary and endogenous compounds that contribute to its regulation of genes in diverse signaling pathways including xenobiotic metabolism, vascular development, immune responses and cell cycle control. However, it is most widely studied for its role in mediating 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) toxicity. The AHR target gene and mono-ADP-ribosyltransferase, TCDD-inducible poly-ADP-ribose polymerase (TIPARP), was recently shown to be part of a novel negative feedback loop regulating AHR activity through mono-ADP-ribosylation. However, the molecular characterization of how AHR regulates TIPARP remains elusive. Here we show that activated AHR is recruited to the TIPARP promoter, through its binding to two genomic regions that each contain multiple AHR response elements (AHREs), AHR regulates the expression of both TIPARP but also TIPARP-AS1, a long non-coding RNA (lncRNA) which lies upstream of TIPARP exon 1 and is expressed in the opposite orientation. Reporter gene and deletion studies showed that the distal AHRE cluster predominantly regulated TIPARP expression while the proximal cluster regulated TIPARP-AS1. Moreover, time course and promoter activity assays suggest that TIPARP and TIPARP-AS1 work in concert to regulate AHR signaling. Collectively, these data show an added level of complexity in the AHR signaling cascade which involves lncRNAs, whose functions remain poorly understood. / This work was supported by Canadian Institutes of Health Research (CIHR) operating grants (MOP-494265 and MOP-125919), an unrestricted research grant from the Dow Chemical Company, and the Johan Throne Holst Foundation to J.M. G.G. was supported by European Union Seventh Framework Program (FP7-PEOPLE2013-COFUND) under the Grant Agreement n609020 - Scientia Fellows

Le développement du séquençage ARN, ou RNAseq, a permis l'essor de la recherche intensive de biomarqueurs dans de nombreux domaines de la biologie. L’information complète du transcriptome contenue dans les données de sorties, permet à un bioinformaticien assidu de dépasser les connaissances actuelles et d’accéder, grâce à des pipelines informatiques avancés, à d’innombrables signatures d’intérêts inédites. Dans cette thèse nous mettons en avant que ces marqueurs potentiels, essentiellement explorés pour répondre à des problématiques clinique en conditions pathologiques, peuvent être utilisés pour affiner la caractérisation de types de cellules sans marqueurs strictement spécifiques. Nous nous sommes intéressés aux cellules souches mésenchymateuses (MSCs), un type de cellules souches adultes multipotentes, fortement utilisées en clinique mais ne possédant pas de marqueurs positifs strictement spécifiques.Notre étude se concentre sur la recherche des ARN longs non-codants non annotés. Ces ARNs, aussi nommés "lncRNA", constituent une classe émergente de transcrits encore peu explorée à ce jour. De plus, cette catégorie démontre une spécificité conditionnelle et tissulaire élevée. Nous avons élaboré un pipeline d’analyse RNAseq optimisé pour la reconstruction et la quantification de lncRNAs non annotés.En utilisant les données publiques de RNAseq, venant de différentes sources de MSCs et d'autres types de cellules, nous avons identifié de nouveaux lncRNA non annotés exprimés spécifiquement dans les MSCs.Nous avons développé pour ce projet Kmerator.jl, un outil qui permet de décomposer un transcrit en sous séquences spécifiques (k-mers) afin de chercher et quantifier plus rapidement la signature de nos candidats dans un grand nombre de données RNAseq. Kmerator a également été utilisé dans d'autres applications pour tester la qualité des données RNA-seq disponibles en accés public.Après validation de ces nouveaux biomarqueurs de MSCs par qPCR, nous avons eu recours à plusieurs outils informatiques pour prédire leurs fonctions potentielles. Enfin, nous avons analysé des données RNAseq « single-cell » pour aborder l’hétérogénéité d’expression au sein des populations MSCs. / The development of RNA sequencing, or RNAseq, have opened the path of intensive biomarkers research in many areas of biology. The complete information of the transcriptome contained in the output data, allows a bioinformatician to surpass the current knowledge and to access, thanks to advanced computer pipelines, to signatures of new interest. In this thesis, we are showing that these potential markers, classically used in clinical and pathological conditions, can be used to characterize cell types without extensive markers profile. We have studied mesenchymal stem cells, a type of adult multipotent stem cells, strongly used in clinics but without strickly specific positive markers. Our study mainly focuses on the search for non-annotated, long non-coding RNAs. These RNAs, also called "lncRNA", constitute an emerging class of transcripts and are still lightly explored.In addition, this category presents a highly tissue-related specificity. We have developed an optimized RNAseq pipeline for the reconstruction and quantification of non-annotated lncRNAs.Using public data from RNAseq, coming from different sources of MSC and other cell types, we have identified new non-annotated lncRNAs clearly and specifically expressed in MSCs. to complete this project, we developed Kmerator.jl, a bioinformatical tool that allows to decompose a transcript in k-mer, and select specific sub-sequences, in order to search and quantify at a faster rate the signature of our candidates in a large number of RNAseq dataset. After validation of these new biomarkers of MSCs by qPCR, we used several computer tools to predict their potential functions. Finally, we analyzed single-cell RNAseq data to address the heterogeneity of expression within MSC populations.

Immer mehr Berichte deuten darauf hin, dass nicht-kodierende RNAs an der Regulation des Immunsystems beteiligt sind. In dieser Arbeit wurden nicht-kodierende RNAs identifiziert, die durch zwei unterschiedliche immunologische Prozesse in zwei verschiedenen Zelltypen reguliert wurden. Zum einen wurde das Transkriptom von Multiplen Myelom-Zellen in Abhängigkeit von der Interleukin 6-Stimulation untersucht. Dabei wurden einige sehr lange, IL 6-regulierte macroRNAs identifiziert, die STAIRs (STAT3-induced RNAs). Bei den STAIRs handelt es sich wahrscheinlich um funktionelle, kontinuierliche, nicht-kodierende macroRNAs, die im Zellkern angereichert sind. Einige STAIRs dienen eventuell zusätzlich oder ausschließlich als Primärtranskript für gespleißte, lange ncRNAs (lncRNAs), die weitere Funktionen in der Zelle ausüben können. Die STAIRs weisen eine große Bandbreite an Gewebsspezifität auf und bei den Untersuchungen in dieser Arbeit zeigten sich Hinweise, dass sie sich für verschiedene Krebserkrankungen als Biomarker eignen könnten. Die zweite Transkriptomanalyse wurde bei der Aktivierung naiver T Zellen durchgeführt. Dabei offenbarte sich, dass die Zellen bei diesem Prozess einen dramatischen Wechsel ihres Transkriptionsprogrammes vollziehen und eine Vielzahl nicht Protein-kodierender Gene reguliert werden. Es wurde die Regulation von ncRNAs, die bisher noch nicht im Zusammenhang mit T Zellen beschrieben wurden, beobachtet und erneut unbekannte, differentiell exprimierte Bereiche identifiziert. Im Anschluss wurde STAIR18, eine nicht-kodierende RNA, die durch die beiden untersuchten Signalwege reguliert wird, eingehender untersucht. Es zeigte sich, dass STAIR18 im menschlichen Genom dupliziert ist und beide Loci die gespleißte, lange ncRNA152 in diversen Varianten transkribieren. ncRNA152 ist hauptsächlich im Zytoplasma lokalisiert und befindet sich dort anscheinend in perinukleären Aggregaten. Die verschiedenen ncRNA152-Isoformen scheinen unter-schiedliche Funktionen auszuführen. Einerseits ist eine Wirkung als competing endogenous RNA wahrscheinlich. Eine weitere Aufgabe der ncRNA152 scheint darin zu bestehen, das STAT3-Primärtranskript zu stabilisieren oder dessen Prozessierung zu fördern.

Proteins and RNAs are two of the most versatile macromolecules that carry out almost all functions within living organisms. In this thesis I have explored evolutionary and regulatory aspects of proteins and RNAs by studying their structures, modifications and interactions. In the first chapter of my thesis I investigate domain atrophy, a term I coined to describe large-scale deletions of core structural elements within protein domains. By looking into truncated domain boundaries across several domain families using Pfam, I was able to identify rare cases of domains that showed atrophy. Given that even point mutations can be deleterious, it is surprising that proteins can tolerate such large-scale deletions. Some of the structures of atrophied domains show novel protein-protein interaction interfaces that appear to compensate and stabilise their folds. Protein-protein interactions are largely influenced by the surface and charge complementarity, while RNA-RNA interactions are governed by base-pair complementarity; both interaction types are inherently different and these differences might be observed in their interaction networks. Based on this hypothesis I have explored the protein-protein, RNA-protein and the RNA-RNA interaction networks of yeast in the second chapter. By analysing the three networks I found no major differences in their network properties, which indicates an underlying uniformity in their interactomes despite their individual differences. In the third chapter I focus on RNA-protein interactions by investigating post-translational modifications (PTMs) in RNA-binding proteins (RBPs). By comparing occurrences of PTMs, I observe that RBPs significantly undergo more PTMs than non-RBPs. I also found that within RBPs, PTMs are more frequently targeted at regions that directly interact with RNA compared to regions that do not. Moreover disorderedness and amino acid composition were not observed to significantly influence the differential PTMs observed between RBPs and nonRBPs. The results point to a direct regulatory role of PTMs in RNA-protein interactions of RBPs. In the last chapter, I explore regulatory RNA-RNA interactions. Using differential expression data of mRNAs and lncRNAs from mouse models of hereditary hemochromatosis, I investigated competing regulatory interactions between mRNA, lncRNA and miRNA. A mutual interaction network was created from the predicted miRNA interaction sites on mRNAs and lncRNAs to identify regulatory RNAs in the disease. I also observed interesting relations between the sense-antisense mRNA-lncRNA pairs that indicate mutual regulation of expression levels through a yet unknown mechanism.

Seul 1,2% du génome code des protéines :98,8% est non-codant,cependant 93% du génome est transcrit, principalement en longs ARN non-codants (lncRNA). Or ces lncRNA constituent une nouvelle classe de régulateurs génomique agissant à tous les niveaux d’expression des gènes et ils sont fortement spécifiques du tissu,modulés au cours du temps et en conditions physiopathologiques.Ainsi,nous proposons que chaque cellule spécifiée exprime son répertoire de lncRNA spécifique avec une carte des zones de chromatines ouvertes renseignant son identité cellulaire.Dans cette perspective,nous avons isolé par FACS 2types cellulaires impliqués dans des pathologies: i) des neurones dopaminergiques humains(nDA) différenciés à partir d’hiPS et ii) des neurones DA et sérotoninergiques (n5-HT)murins.Sur ces 2types neuraux isolés,nous avons identifié 1363 lncRNA exprimés dans les nDA (dont 989nouveaux) constituant le répertoire des neurones DA et 1257 lncRNA dans les n5-HT (719nouveaux) constituant le répertoire des n5-HT.Or leur comparaison a montré que seuls 194 lncRNA sont communs aux 2types cellulaires:la majorité des lncRNA est exprimée soit dans les nDA soit dans les n5-HT,attestant leur spécificité cellulaire.De plus,39%des zones de chromatines ouvertes/potentiellement régulatrices des nDA ne sont pas non plus retrouvées dans les n5-HT.Ainsi, nous avons généré un catalogue d’éléments non codants constituant des signatures moléculaires spécifiques des nDA et n5-HT,ouvrant de nouvelles pistes physiopathologiques:Dans cette optique,les signatures non codantes DA ont été comparées avec les SNP associés à la maladie de Parkinson et des études de fonction sur des lncRNA candidats ont été réalisées. / Only 1.2% of the genome codes for proteins; 98.8% is thus non-coding, despite 93% of the human genome being actively transcribed, mostly in long non-coding RNA (lncRNA).These lncRNA constitute a new class of genomic regulator capable of acting at all levels of gene expression and their expression is highly tissue-specific,modulated during the time and under normal/pathological conditions.Thus, we propose that each specified cell expresses a specific repertoire of lncRNA correlated to open/active chromatin regions specifying its cellular identity.In this context, we isolated by FACS 2neural types involved in many pathologies: i) human dopaminergic neurons (nDA) differentiated from hiPS and ii) DA and serotoninergic (n5-HT) neurons. From these 2neural types, we identified 1,363 lncRNA in nDA (among which 989 new, whether 73%) constituting the repertoire of nDA, and 1,257 lncRNA (among which 719 new) constituting the repertoire of n5-HT. Moreover,their comparison has shown that only 194 lncRNA are common to both neural types:thus the majority of lncRNA is expressed either in nDA or in n5-HT, indicating a high degree of cell-specificity.In addition, 39% of open chromatin regions, potentially regulatory, were also not detected in the n5-HT.Thus, we have generated DA and 5-HT specific catalogues of non-coding elements of the genome, which constitute DA and 5-HT specific molecular signatures, that could participate in deepening our knowledge regarding nDA or n5-HT development and dysfunctions. With this in mind,these DA specific elements have been compared with the SNP described as Parkinson Disease risk variants and candidate lncRNA were selected to perform studies of function.

Le couple télomère/télomérase apparaît comme une cible prometteuse pour de potentiels agents anticancéreux qui seraient actifs sur un large éventail de tumeurs. Le laboratoire d’accueil a montré dans un modèle de leucémie aiguë promyélocytaire (LAP), qu'un agent utilisé en clinique, l'acide rétinoïque (ATRA), exerce une activité anti-tumorale en réprimant la transcription de la sous-unité catalytique hTERT indépendamment de la différenciation. Ce modèle (NB4) avec ses variants cellulaires résistant (NB4-LR1SFD) ou non à la répression de hTERT (NB4-LR1) par l’ATRA constitue un outil de choix pour l’identification de facteurs régulateurs de hTERT et la recherche des bases moléculaires de sa réactivation.Une approche transcriptomique a été utilisée afin d’identifier de nouveaux gènes et/ou réseaux de signalisation induits par l’ATRA et régulateurs de hTERT. L’analyse bioinformatique nous a permis de construire des profils d’expression différentielle entre les 2 lignées et des réseaux d’interaction. Parmi les candidats, H19, un ARN long de 2.5Kb, polyadénylé et non codant. H19 est classé parmi les gènes supresseurs de tumeurs : en son absence il y a développement de cancer (cas de la tumeur de Wilms, rhabdomyosarcome embryonnaire, Syndrome Beekwith-Wiedman) ; sa réintroduction par transfection conduit à une perte de tumoriginicité. Cependant H19 est reconnu de plus en plus comme un oncogène vu que son expression est élevée dans plusieurs types de cancers solides. Par contre peu d’études s’intéressent au rôle de H19 dans les leucémies, d’où notre intérêt pour l’étudier dans le modèle LAP que nous avons développé.Nous avons mis au point la mesure d’expression de H19 par RT-PCR quantitative, validé les données obtenues dans l’analyse transcriptomique et montré que le traitement ATRA induit l’expression de H19 dans les cellules NB4-LR1 alors que cette expression est plutôt diminuée dans les cellules NB4-LR1SFD. L’induction observée dans les cellules NB4-LR1 existe indépendamment de la différenciation. Par contre, cette induction peut être observée associée à la différenciation ou à l’apoptose dans la lignée cellulaire NB4-LR1SFD parallèlement à une diminution importante de l’expression de hTERT. Ce résultat important montre que la lignée NB4-LR1SFD ne présente pas de défaut général d’induction de H19. Ces données suggèrent l’existence d’une corrélation inverse entre le niveau d’expression de hTERT et celui de H19 dans ce modèle cellulaire. De façon importante, l’analyse des banques de données issues de patients LAP publiquement accessibles retrouve cette corrélation inverse.Une diminution d’activité télomérasique est observée dans des extraits cellulaires incubés en présence de l’ARN H19 transcrit in vitro. Cette diminution d’activité est observée aussi après surexpression de H19 in cellulo. Les expériences de RIP (RNA immunoprecipitation) ont montré une diminution de la quantité de hTR lié à hTERT suite à une augmentation d’expression de H19 après traitement ATRA in vitro ou après surexpression de H19 in cellulo. Une hypothèse serait que H19 induirait un déplacement de hTR du complexe hTR-hTERT. Cependant, les expériences de « pull-down » n’ont pas réussi à confirmer l’hypothèse d’une interaction possible entre l’ARN H19 et la protéine TERT.Mon travail de thèse identifie pour la première fois H19, un ARN long non codant, comme facteur régulateur potentiel de hTERT pouvant modifier son activité. Ce travail proposerait non seulement un mécanisme nouveau de régulation de l’activité télomérase mais aussi une fonction nouvelle pour H19 dans ce type de cancer. / The telomere / telomerase pair appears to be a promising target for potential anticancer agents that would be active on a wide range of tumors. The host laboratory has shown in a model of acute promyelocytic leukemia (APL), that a clinically used agent, retinoic acid (ATRA), exerts anti-tumor activity by repressing the transcription of the catalytic subunit hTERT regardless of differentiation. This model (NB4) with its resistant cell variants (NB4-LR1SFD) or not to the repression of hTERT (NB4-LR1) by ATRA is a tool of choice for the identification of hTERT regulatory factors and the search for molecular bases of its reactivation.A "microarray" approach has been used to identify new ATRA-mediated genes and / or signaling networks and potential hTERT regulators. Bioinformatic analysis allowed us to build differential expression profiles between the 2 lineages and interaction networks. Among the candidates, H19, a 2.5Kb long, polyadenylated and non-coding RNA. H19 is classified as a tumor suppressor gene: in its absence there is cancer development (case of Wilms tumor, embryonic rhabdomyosarcoma, Beckwith-Wiedman syndrome); its reintroduction by transfection leads to a loss of tumorigenicity. However H19 is increasingly recognized as an oncogene as its expression is elevated in several types of solid cancers. However, few studies are interested in the role of H19 in leukemias, hence our interest in studying it in the APL model that we have developed.We developed the H19 expression measurement by quantitative RT-PCR, validated the data obtained in the "microarray" analysis and showed that the ATRA treatment induces the expression of H19 in NB4-LR1 cells whereas this expression is rather diminished in NB4-LR1SFD cells. The induction observed in NB4-LR1 cells exists independently of differentiation. On the other hand, this induction can be observed associated with the differentiation or apoptosis in the NB4-LR1SFD cell line in parallel with a significant decrease in the expression of hTERT. This important result shows that the NB4-LR1SFD line does not have a general H19 induction defect. These data suggest the existence of an inverse correlation between the expression level of hTERT and that of H19 in this cellular model. Importantly, the analysis of publicly accessible APL patients’ databases finds this inverse correlation as well.We observed a decrease in telomerase activity in cellular extracts incubated in the presence of in vitro transcribed H19 RNA. This decrease in activity was also observed after overexpression of H19 in cellulo. The RIP (RNA immunoprecipitation) experiments showed a decrease in hTR amount bound to hTERT following an increase in H19 expression after ATRA treatment in vitro or after overexpression of H19 in cellulo. We hypothesize that H19 induces a displacement of hTR from the hTR-hTERT complex. However, the "pull-down" experiments failed to confirm the hypothesis of a possible interaction between H19 RNA and TERT protein.My thesis work identifies, for the first time, the long non-coding RNA H19, as a potential regulator of hTERT that can modify its activity. This work would propose not only a new mechanism of regulation of telomerase activity but also a new function for H19 in this type of cancer.

La maladie de Hirschsprung est une affection congénitale de la motilité intestinale caractérisée par un segment aganglionnaire dans le côlon terminal. Un criblage génétique par mutation insertionnelle aléatoire chez la souris nous a permis d’identifier la lignée transgénique Spot dont les homozygotes souffrent de mégacôlon aganglionnaire. L’analyse d’intestins d’embryons mutants a révélé une baisse de prolifération et un délai de migration des cellules de la crête neurale entériques (CCNe) progénitrices dus à leur différenciation gliale précoce, entrainant un défaut de colonisation de l’intestin et une aganglionose du côlon. Le séquençage du génome Spot indique que le transgène s’est inséré à l’intérieur du locus K12-Nr2f1 sur le chromosome 13, une région dépourvue de gènes préalablement associés à la maladie, perturbant également une séquence non-codante très conservée dans l’évolution. K12 est un gène d’ARN long non codant (ARNlnc) et antisens du gène Nr2f1, lui-même impliqué dans la gliogénèse du système nerveux central. Le séquençage du transcriptome des CCN a montré une surexpression de Nr2f1 et des formes courtes de K12 chez Spot et des essais luciférase ont révélé l’activité répressive de l’élément conservé. Nous avons observé l’expression de K12 dans les CCNe et sa localisation subcellulaire dans des zones transcriptionnellement actives du noyau. Avec l’émergence des ARNlnc régulateurs, ces données nous permettent de pointer deux nouveaux gènes candidats associés à une différenciation gliale prématurée du SNE menant au mégacôlon aganglionnaire, en supposant que la régulation de Nr2f1 se fait par son antisens, K12. / Hirschsprung disease is a congenital intestinal motility disorder characterized by an aganglionic segment in the distal colon. A genetic screen performed via random insertional mutagenesis in mice allowed identifying the Spot line, whose homozygotes suffer from an aganglionic megacolon. The analysis of mutant embryonic intestines revealed a decreased proliferation rate and a delay in migration of the enteric neural crest cell (eNCC) progenitors, secondary to their early glial differentiation, resulting in failure to properly colonize the intestine. Sequencing of the Spot genome indicated that the transgene was inserted into the K12-Nr2f1 locus on chromosome 13, a region devoid of genes associated with the disease, and disrupted in addition a highly conserved non-coding sequence. K12 is an uncharacterized long non-coding RNA (LncRNA) gene antisense to the Nr2f1 gene, which is involved in gliogenesis in the central nervous system. Sequencing of the eNCC transcriptome revealed an overexpression of Nr2f1 and short forms of K12 in Spot, and luciferase assays showed repressive activity of the conserved element. We observed the expression of K12 in the eNCC and its subcellular localization in transcriptionally active zones of the nucleus. With the recent emergence of LncRNA regulators and supposing that the regulation of Nr2f1 is done by its antisense K12, these data allowed us identifying two new candidate genes associated with a premature glial differentiation leading to aganglionic megacolon.

L'expression du gène Igf2, qui est soumis à l'empreinte génomique parentale chez les mammifères, est hautement régulée au cours du développement embryonnaire et de la période périnatale grâce à divers mécanismes transcriptionnels et post-transcriptionnels. Ces mécanismes mettent à contribution de longs ARN non codants produits au sein même du locus, dont le plus connu est l'ARN H19. En utilisant une approche de complémentation génétique par un transgène H19 dans myoblastes H19 KO de souris, nous démontrons l'existence de plusieurs nouveaux promoteurs d'Igf2. L'un de ces promoteurs, qui est conservé chez l'homme, peut être activé par un ARN ectopique antisens d'H19 (lncARN 91H) en dépit d'une méthylation complète de la région de contrôle empreinte située en cis sur le même allèle. Nous montrons également que les lncARN 91H présentent une certaine spécificité tissulaire et que leur transcription peut être initiée à partir des séquences conservées CS4, CS5 et CS9 situées en aval du gène H19. Quant à l'ARN H19, qui est l'ARN non codant majeur du locus, il semble pouvoir réguler ses transcrits antisens dans les myoblastes H19 KO complémentés par le transgène H19, mais surtout il participe activement à la régulation post-transcriptionnelle du gène Igf2 chez la souris. Nous observons en effet qu'il favorise la coupure endoribonucléolytique de l'ARN Igf2 par un mécanisme qui reste à découvrir. Enfin, nous mettons en évidence l'existence d'un l'arrêt de l'élongation de la transcription du gène d'Igf2, pour lequel nous proposons un modèle de régulation faisant intervenir un autre long ARN non codant du locus: le lncARN PIHit. Au-delà des mécanismes qui restent à explorer, nos résultats renforcent l'idée que la structure tridimensionnelle de la chromatine participe à la régulation de l'expression des gènes chez les mammifères. / In mammals, the expression of the Igf2 gene, which is subject to parental genomic imprinting, is tightly regulated during embryonic development and the perinatal period through several transcriptional and post-transcriptional mechanisms. These mechanisms are involving long non-coding RNAs (lncRNAs) produced within the locus; among them the best known is probably the H19 RNA. Using a genetic complementation assay consisting in transfections of an H19 transgene into H19 KO myoblasts, we discovered several novel Igf2 promoters in the mouse. One of these promoters, that is conserved in the human, can be activated by ectopic H19 antisens RNAs (91H lncRNAs) despite a complete methylation of the Imprinting-Control Region located in cis on the same allele. We also show that the 91H lncRNAs possess some tissue-specific features and that their transcription can be initiated from the CS4, CS5 and CS9 conserved sequences located downstream of the H19 gene. On the other hand, the H19 RNA, that is the major lncRNA of the locus, appears to regulate its antisense transcripts in H19 KO myoblasts complemented with the H19 transgene, but its major function seems to be in regulating post-transcriptionally the Igf2 gene expression. Indeed, we have observed that it favours the endoribonucleolytic cleavage of the Igf2 messenger RNAs through a mechanism that remains to be elucidated. Finally, we reveal the existence of a premature transcriptional elongation stop of the Igf2 gene, for which we propose a regulation model involving another lncRNA of the locus: the PIHit lncRNA. Beyond the mechanisms that remain to be explored, our results strengthen the idea that, in mammals, the three-dimensional organization of the chromatin is involved in regulating gene expression.

A dengue é uma infecção viral sistêmica que pode se manifestar clinicamente de diversas formas, desde febres leves a hemorragia e síndrome do choque, condições potencialmente fatais. Diversos estudos já foram publicados investigando as mudanças globais de expressão que ocorrem durante a evolução da doença nesses diferentes quadros clínicos. Porém, nenhum desses estudos analisou o papel dos RNAs não codificadores longos (lncRNAs) na progressão da doença. Neste projeto, foi realizada uma metanálise dos dados de expressão provenientes desses estudos de dengue focando na expressão de lncRNAs e seus possíveis mecanismos de regulação gênica. Foram identificados dezenas de lncRNAs cuja expressão aumenta ou diminui em pacientes infectados com dengue comparado com pessoas saudáveis. Através de análise de \"guilty-by-association\", procurou-se identificar genes codificadores de proteína possivelmente regulados por esses lncRNAs ou genes que os regulem. Nossos resultados fornecem evidência de novos mecanismos de regulação entre lncRNAs e mRNAs. / Dengue fever is a systemic viral infection that can manifest clinically in a variety of ways, from mild fever to potentially fatal conditions such as hemorrhage and shock syndrome. Several studies have already been published investigating the global changes in expression that occur during the evolution of the disease in these different clinical settings. However, none of these studies analyzed the role of long non-coding RNAs (lncRNAs) in disease progression. In this project, we performed a meta-analysis of transcriptome data obtained from these dengue studies and focused on the expression of lncRNAs and their possible mechanisms of gene regulation. Dozens of lncRNAs have been identified whose expression increases or decreases in patients infected with dengue compared to healthy individuals. Through guilty-by-association analysis, we identified several lncRNAs that possibly regulate protein coding genes. Our results provide evidence of novel regulatory mechanisms between lncRNAs and mRNAs.